It is estimated that drug-resistant infections could cause 10 million deaths each year by 2050 and an annual economic cost of £69 trillion. Prototypes for a treatment screening platform to enable high throughput testing of new therapies and accelerate their translation. Prototype point-of-care diagnostic devices for both medical and agricultural use to reduce inappropriate use of antibiotics. The projects announced today exemplify this potential and may play a key role in improving the lives of millions of people.' We are very grateful to the EPSRC for supporting our efforts to tackle this crisis in a completely novel way.'
